Hubei Goto Biopharm Co.Ltd.
Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.
Hubei Goto Biopharm Co.Ltd. (300966) - Net Assets
Latest net assets as of September 2025: CN¥957.91 Million CNY
Based on the latest financial reports, Hubei Goto Biopharm Co.Ltd. (300966) has net assets worth CN¥957.91 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.86 Billion) and total liabilities (CN¥1.90 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥957.91 Million |
| % of Total Assets | 33.53% |
| Annual Growth Rate | 18.99% |
| 5-Year Change | 87.95% |
| 10-Year Change | N/A |
| Growth Volatility | 17.41 |
Hubei Goto Biopharm Co.Ltd. - Net Assets Trend (2017–2024)
This chart illustrates how Hubei Goto Biopharm Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hubei Goto Biopharm Co.Ltd. (2017–2024)
The table below shows the annual net assets of Hubei Goto Biopharm Co.Ltd. from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.01 Billion | -0.89% |
| 2023-12-31 | CN¥1.02 Billion | +4.35% |
| 2022-12-31 | CN¥981.14 Million | +18.44% |
| 2021-12-31 | CN¥828.42 Million | +53.45% |
| 2020-12-31 | CN¥539.85 Million | +12.18% |
| 2019-12-31 | CN¥481.25 Million | +17.88% |
| 2018-12-31 | CN¥408.26 Million | +35.88% |
| 2017-12-31 | CN¥300.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hubei Goto Biopharm Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 435.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥290.81 Million | 31.50% |
| Common Stock | CN¥115.28 Million | 12.49% |
| Other Comprehensive Income | CN¥108.11 Million | 11.71% |
| Other Components | CN¥408.94 Million | 44.30% |
| Total Equity | CN¥923.14 Million | 100.00% |
Hubei Goto Biopharm Co.Ltd. Competitors by Market Cap
The table below lists competitors of Hubei Goto Biopharm Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Metrodata Electronics Tbk
JK:MTDL
|
$170.60 Million |
|
Cheetah Mobile Inc
NYSE:CMCM
|
$170.64 Million |
|
Truxton Corporation
PINK:TRUX
|
$170.71 Million |
|
Sunlour Pigment CO.LTD.
SHE:301036
|
$170.72 Million |
|
Ziprecruiter Inc
NYSE:ZIP
|
$170.54 Million |
|
Polimex-Mostostal S.A.
WAR:PXM
|
$170.43 Million |
|
Électricite de Strasbourg Société Anonyme
PA:ELEC
|
$170.40 Million |
|
HARMONY ENERGY INCOME TR.
F:WF0
|
$170.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hubei Goto Biopharm Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 952,749,525 to 923,137,679, a change of -29,611,846 (-3.1%).
- Net loss of 27,591,132 reduced equity.
- Dividend payments of 25,692,538 reduced retained earnings.
- Other comprehensive income increased equity by 63,786.
- Other factors increased equity by 23,608,038.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-27.59 Million | -2.99% |
| Dividends Paid | CN¥25.69 Million | -2.78% |
| Other Comprehensive Income | CN¥63.79K | +0.01% |
| Other Changes | CN¥23.61 Million | +2.56% |
| Total Change | CN¥- | -3.11% |
Book Value vs Market Value Analysis
This analysis compares Hubei Goto Biopharm Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.29x to 2.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥6.52 | CN¥21.43 | x |
| 2018-12-31 | CN¥4.85 | CN¥21.43 | x |
| 2019-12-31 | CN¥4.17 | CN¥21.43 | x |
| 2020-12-31 | CN¥4.64 | CN¥21.43 | x |
| 2021-12-31 | CN¥7.00 | CN¥21.43 | x |
| 2022-12-31 | CN¥8.05 | CN¥21.43 | x |
| 2023-12-31 | CN¥8.28 | CN¥21.43 | x |
| 2024-12-31 | CN¥8.01 | CN¥21.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hubei Goto Biopharm Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.14%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 3.02x
- Recent ROE (-2.99%) is below the historical average (8.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 15.79% | 14.22% | 0.69x | 1.61x | CN¥17.39 Million |
| 2018 | 17.31% | 16.16% | 0.71x | 1.51x | CN¥29.85 Million |
| 2019 | 15.17% | 15.70% | 0.57x | 1.70x | CN¥24.87 Million |
| 2020 | 9.97% | 11.38% | 0.58x | 1.50x | CN¥-165.51K |
| 2021 | 9.71% | 13.26% | 0.49x | 1.50x | CN¥-2.37 Million |
| 2022 | 4.33% | 6.65% | 0.29x | 2.23x | CN¥-52.60 Million |
| 2023 | 2.41% | 4.06% | 0.23x | 2.57x | CN¥-72.27 Million |
| 2024 | -2.99% | -5.14% | 0.19x | 3.02x | CN¥-119.90 Million |
Industry Comparison
This section compares Hubei Goto Biopharm Co.Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hubei Goto Biopharm Co.Ltd. (300966) | CN¥957.91 Million | 15.79% | 1.98x | $170.60 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |